Plot No. C40, Road No. 21Y, MIDC, Wagle Industrial Estate,
Thane(W)-400604, MH, India.
Your enquiry has been submitted
Something problem with the server. Try again.
Intended Use
Recommended for cultivation of fastidious pathogenic bacteria, yeasts and moulds.
Composition
| Ingredients | Gms / Litre |
|---|---|
| HM Infusion powder # | 12.5000 |
| BHI Powder$ | 5.000 |
| Proteose peptone | 10.000 |
| Dextrose (Glucose) | 2.000 |
| Sodium chloride | 5.000 |
| Disodium hydrogen phosphate | 2.500 |
| Agar | 15.000 |
| Final pH (at 25°C) | 7.4±0.2 |
Formula adjusted, standardized to suit performance parameters
# Equivalent to Calf brain, infusion from
$ Equivalent to Beef heart, infusion from
Directions
Each capsule contains 13 grams of media. Suspend 1 capsule in 250 ml (4 capsules in 1000 ml) distilled or purified water. Heat to boiling to dissolve the medium completely. Sterilize by autoclaving at 15 lbs pressure (121°C) for 15 minutes. Cool to 45-50°C. Mix well and pour into sterile Petri plates. If desired, 20 units Penicillin and 40 µg Streptomycin per ml of medium may be added to make the medium selective for fungi.
Principle And Interpretation
Brain Heart Infusion Agar is highly nutritious and can support luxuriant growth of wide variety of microorganisms. It can be further enriched by the addition of blood or rendered selective by adding different antibiotics (2,8). It is a general purpose medium used for primary isolation of aerobic bacteria from clinical specimens. Addition of 50 mg/l chloramphenicol or 40mg/l streptomycin or a mixture of 50mg/l gentamicin and 50mg/l chloramphenicol along with 5-10% sterile defibrinated blood is often recommended for inhibition of bacteria and isolation of pathogenic systemic fungi. A mixture of cycloheximide (0.5 g/l) and chloramphenicol (0.05 g/l) is also used for selective isolation of pathogenic fungi (incubation at 25-30°C for 1-2 weeks) (6). Some fungi may be inhibited on this medium with 10% sheep blood, gentamicin and chloramphenicol (1,3,7). Proteose peptone, HM Infusion powder and BHI Powder used in the media serves as sources of carbon, nitrogen, vitamins, amino acids, along with essential growth factors. Dextrose is the energy source. Sodium chloride maintains the osmotic equilibrium of the medium while disodium phosphate buffers the medium. Defibrinated sheep blood added to the basal medium provides essential growth factors for the more fastidious fungal organisms.
Type of specimen
Clinical samples
Specimen Collection and Handling
For clinical samples follow appropriate techniques for handling specimens as per established guidelines (4,5). After use, contaminated materials must be sterilized by autoclaving before discarding.
Warning and Precautions
In Vitro diagnostic use only. Read the label before opening the container. Wear protective gloves/protective clothing/eye protection/face protection. Follow good microbiological lab practices while handling specimens and culture. Standard precautions as per established guidelines should be followed while handling clinical specimens. Safety guidelines may be referred in individual safety data sheets.
Limitations
- As organisms differ in their nutritional requirements, some fastidious organisms may be inhibited or may show poor growth.
- Further biochemical tests must be carried out for complete identification.
Quality Control
Appearance: Gelatin capsule containing cream to yellow coloured granular media
Gelling: Firm, comparable with 1.5% Agar gel
Colour and Clarity of prepared medium: Basal medium: Light amber coloured clear to slightly opalescent gel. After addition of 5% v/v sterile defibrinated blood : Cherry red coloured, opaque gel forms in Petri plates.
Quantity: Each capsule contains 13 grams of medium for 250 ml media
Reaction: Reaction of 5.2% w/v aqueous solution at 25°C. pH : 7.4±0.2
pH: 7.20-7.60
Cultural Response
Cultural characteristics observed after an incubation at 35-37°C for 18-24 hours (If desired add 5% v/v sterile defibrinated blood).
| Organism | Inoculum (CFU) | Growth | Recovery | Growth w/ blood | Recovery w/ blood |
|---|---|---|---|---|---|
| Candida albicans ATCC 26790 | 50-100 | luxuriant | >=70% | luxuriant | >=70% |
| Escherichia coli ATCC 25922 (00013*) | 50-100 | luxuriant | >=70% | luxuriant | >=70% |
| Shigella flexneri ATCC 12022 (00126*) | 50-100 | luxuriant | >=70% | luxuriant | >=70% |
| Staphylococcus aureus subsp. aureus ATCC 25923 (00034*) | 50-100 | luxuriant | >=70% | luxuriant | >=70% |
| Streptococcus pneumoniae ATCC 6303 | 50-100 | luxuriant | >=70% | luxuriant | >=70% |
Key: *Corresponding WDCM numbers.
Storage and Shelf Life
Store between 10- 30°C in a tightly closed container and the prepared medium at 2 - 8°C. Use before expiry date on the label. On opening, product should be properly stored dry, after tightly capping the bottle in order to prevent lump formation due to the hygroscopic nature of the product. Improper storage of the product may lead to lump formation. Store in dry ventilated area protected from extremes of temperature and sources of ignition Seal the container tightly after use. Product performance is best if used within stated expiry period.
Disposal
User must ensure safe disposal by autoclaving and/or incineration of used or unusable preparations of this product. Follow established laboratory procedures in disposing of infectious materials and material that comes into contact with clinical sample must be decontaminated and disposed of in accordance with current laboratory techniques (4,5).
| Product Name | HiEncap™ BHI Agar (HiEncap™ Special Infusion Agar) |
|---|---|
| SKU | EC211CCL |
| Application/ Industry | Clinical |
| Product Type | HiEncap™ |
| Physical Form | Granulated Media in Gelatin Capsule |
| Origin | Animal |
| Packaging type | HDPE Jar |
| References | 1. Roseburg T. et al, 1944, J. Infect. Dis., 74:131. 2. Conant N. F., 1950, Diagnostic Procedures and Reagents, 3rd Ed., APHA Inc. 3. MacFaddin J. F., 1985, Media for Isolation-Cultivation-Identification-Maintenance of Medical Bacteria, Vol. I, Williams and Wilkins, Baltimore. 4. Creitz and Puckett, 1954, Am. J. Clin. Pathol., 24:1318.5.Murray P. R., Baron J. H., Pfaller M. A., Jorgensen J. H. and Yolken R. H., (Eds.), 2003, Manual of Clinical Microbiology, 8th Ed., American Society for Microbiology, Washington, D.C.6.Ajello L., Georg L., Kaplan W. and Kaufman L., 1963, CDC Laboratory Manual for Medical Mycology, PHS Publication No. 994, U.S. Govt. Office, Washington, D.C. |
| Customized Product Available | No |
Write Your Own Review
